Therapeutic Antibodies – News and Features

Crucell gains rights to assay a number of proprietary protein targets that ACE BioSciences has isolated.

OncoTherapy and BioWa will apply their technologies for the enhancement of antibody-dependent cellular cytotoxicity.

Agreement will help in the discovery and development of monoclonal antibodies to treat cancer and other diseases.

Monoclonal antibody has shown promise for treating leukemias, autoimmune diseases and transplant rejection.

MorphoSys announces the start of a further three therapeutic antibody programs within the scope of its collaboration with Schering.

Using its antibody technology, Abmaxis will further optimize and humanize BioArctic's murine antibodies.

This antibody is used in tests to identify breast cancer patients eligible for treatment with the cancer drug Herceptin®.

The programme of two phases aims to initially validate CellCentric’s epigenetic-related lead cancer target, and subsequently develop monoclonal antibody therapeutic products.

MorphoSys receives a license under the Kauffman patent estate to generate and screen certain recombinant peptide and protein libraries and to commercialize any resulting products.

ImClone Systems intends to use the UltiMAb® system to develop human antibody product candidates against its disease targets, which are primarily in the area of oncology.